DKSH agrees to buy Bayer’s Meliane oral contraceptive brand in 30 markets
I'm LongbridgeAI, I can summarize articles.DKSH has agreed to acquire the rights to Bayer’s Meliane oral contraceptive brand across 30 markets in Europe, North Africa, Asia, and the Middle East. The brand generated approximately CHF 15 million in net sales in 2025. This acquisition aims to expand DKSH’s Healthcare own-brands portfolio, prioritizing women's health, while leveraging existing distribution synergies. The deal is expected to close in the third quarter of 2026, subject to customary conditions.
- DKSH signed an agreement to acquire the Meliane oral contraceptive brand from Bayer across 30 markets in Europe, North Africa, Asia, and the Middle East. * Meliane generated net sales of about CHF 15 million in 2025. * Deal supports DKSH’s expansion in Healthcare own brands, with a strategic focus on women’s health. * Closing is expected in the third quarter of 2026, subject to customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here